BASINGSTOKE, England, February 23 /PRNewswire-FirstCall/ -- The Company was notified by Mr Angus Russell, Chief Financial Officer on 22 February 2007 of the exercise in London on the same day, of an option over 6,422 ordinary 5p shares in the capital of the Company at an exercise price of GBP10.275.
The Company was further notified by Mr Russell on 22 February 2007 of the sale in London on the same day of 6,085 ordinary 5p shares in the capital of the Company at a price of GBP11.35, Mr Russell having retained the balance of 337 shares.
The options exercised by Mr Russell were granted on 1 March 2000 and were due to expire on 1 March 2007.
T May Company Secretary For further information please contact: Investor Relations Clea Rosenfeld (Rest of the World) +44-1256-894-160 Brian Piper (North America) +1-484-595-8252 Notes to editors SHIRE PLC
Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.
Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
For further information on Shire, please visit the Company’s website: www.shire.com.
Shire PLC
CONTACT: Investor Relations, Clea Rosenfeld (Rest of the World),+44-1256-894-160, Brian Piper (North America), +1-484-595-8252
